Fig. 1.

Kaplan-Meier survival curves. a among patients with baseline brain metastases, comparing patients who received brain radiotherapy prior to crizotinib (prior-RT) versus those who did not (Non prior-RT), b among patients with crizotinib treatment failure, comparing patients who received salvage radiation post initial disease progression (post-RT) versus those who did not (Non post-RT), c among patients with crizotinib treatment failure, comparing patients who continued crizotinib administration beyond progressive disease (CBPD) versus those who did not (Non-CBPD), d comparing patients who received radiotherapy during their treatment course (RT) versus those who did not (Non-RT), in the whole population